Active, not recruitingPHASE1, PHASE2NCT05546268
Study of Oral MRT-2359 in Selected Cancer Patients
Studying NON RARE IN EUROPE: Non-small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Monte Rosa Therapeutics, Inc
- Intervention
- Oral MRT-2359(drug)
- Enrollment
- 174 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2027
Study locations (17)
- Honor Health Research Institute, Scottsdale, Arizona, United States
- University of California San Diego, San Diego, California, United States
- Yale University, New Haven, Connecticut, United States
- University of Kansas Cancer Center, Lawrence, Kansas, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Henry Ford Cancer Institute, Detroit, Michigan, United States
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan, United States
- Washington University, St Louis, Missouri, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Columbia University Irving Medical Centre, New York, New York, United States
- Sarah Cannon Research Institute, Nashville, Tennessee, United States
- Mary Crowley Cancer Research, Dallas, Texas, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States
- South Texas Accelerated Research Therapeutics (START) Mountain Region, West Valley City, Utah, United States
- +2 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05546268 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Non-small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06878274Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLCCentre hospitalier de l'Université de Montréal (CHUM)
- RECRUITINGPHASE3NCT07251582Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung CancerHunan Province Tumor Hospital
- RECRUITINGPHASE2NCT06946797A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)Bristol-Myers Squibb
- RECRUITINGPHASE2NCT07086456Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung CancerSun Yat-sen University
- RECRUITINGNANCT07086300Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLCKong Fanming
- RECRUITINGPHASE2NCT06620835Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by BrigatinibGroupe Francais De Pneumo-Cancerologie
- RECRUITINGPHASE1, PHASE2NCT06922591Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC PatientsTango Therapeutics, Inc.
- RECRUITINGPHASE3NCT07050043Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLCDr Arvindran A/L Alaga
See all trials for NON RARE IN EUROPE: Non-small cell lung cancer →